192 related articles for article (PubMed ID: 17953912)
1. [Viral safety measures of plasma for transfusion and applicability in Spain].
Pereira A
Med Clin (Barc); 2007 Oct; 129(12):458-68. PubMed ID: 17953912
[No Abstract] [Full Text] [Related]
2. Virus inactivation of fresh plasma.
Mohr H
Vox Sang; 1998; 74 Suppl 2():171-2. PubMed ID: 9704442
[No Abstract] [Full Text] [Related]
3. Approaches to the reduction of viral infectivity in cellular blood components and single donor plasma.
Wagner SJ; Friedman LI; Dodd RY
Transfus Med Rev; 1991 Jan; 5(1):18-32. PubMed ID: 1802274
[No Abstract] [Full Text] [Related]
4. Genomic screening for blood-borne viruses in transfusion settings.
Lee HH; Allain JP
Vox Sang; 1998; 74 Suppl 2():119-23. PubMed ID: 9704433
[No Abstract] [Full Text] [Related]
5. Inactivation of viruses in blood and plasma products.
Suomela H
Transfus Med Rev; 1993 Jan; 7(1):42-57. PubMed ID: 8431658
[No Abstract] [Full Text] [Related]
6. Influence of methylene blue photoinactivation treatment on coagulation factors from fresh frozen plasma, cryoprecipitates and cryosupernatants.
Aznar JA; Bonanad S; Montoro JM; Hurtado C; Cid AR; Soler MA; De Miguel A
Vox Sang; 2000; 79(3):156-60. PubMed ID: 11111234
[TBL] [Abstract][Full Text] [Related]
7. Reducing the residual risk of transfusion-transmitted viruses: mini-pool or single-donation NAT?
Roth WK; Seifried E
Transfusion; 2001 Jun; 41(6):845-7. PubMed ID: 11399831
[No Abstract] [Full Text] [Related]
8. Viral inactivation of fresh frozen plasma.
Pamphilon D
Br J Haematol; 2000 Jun; 109(4):680-93. PubMed ID: 10929016
[No Abstract] [Full Text] [Related]
9. Kill and cure. The hope and reality of virus inactivation.
Prowse C
Vox Sang; 1994; 67 Suppl 3():191-6. PubMed ID: 7975491
[No Abstract] [Full Text] [Related]
10. Virally inactivated fresh frozen plasma.
Williamson LM; Allain JP
Vox Sang; 1995; 69(3):159-65. PubMed ID: 8578727
[TBL] [Abstract][Full Text] [Related]
11. Further enhancement of the safety of human plasma derivatives.
Lamb C
Transfusion; 2002 Aug; 42(8):973-4. PubMed ID: 12385405
[No Abstract] [Full Text] [Related]
12. [Quarantine and plasmapheresis].
Ortiz Pareja M; Terol Fernández E; Hernández Lamas MC; Sánchez Gordo F
Sangre (Barc); 1998 Jun; 43(3):261-2. PubMed ID: 9741240
[No Abstract] [Full Text] [Related]
13. [Safety of transfusion therapy with special emphasis on inactivated viruses in products made from human blood].
Patko MS; Balija M; Grgicević D
Lijec Vjesn; 1995; 117(9-10):216-21. PubMed ID: 8643012
[TBL] [Abstract][Full Text] [Related]
14. Emerging viruses and transfusion.
Allain JP
Transfus Clin Biol; 2001 Jun; 8(3):220-1. PubMed ID: 11499963
[TBL] [Abstract][Full Text] [Related]
15. Safety of human albumin as a constituent of biologic therapeutic products.
McClelland DB
Transfusion; 1998 Jul; 38(7):690-9. PubMed ID: 9683109
[No Abstract] [Full Text] [Related]
16. [Transfusion safety and hemosurveillance].
Romeiras MC
Acta Med Port; 2000; 13(4):199-202. PubMed ID: 11155487
[TBL] [Abstract][Full Text] [Related]
17. Solvent/detergent-treated plasma: a tale of 30 years of experience.
Liumbruno GM; Marano G; Grazzini G; Capuzzo E; Franchini M
Expert Rev Hematol; 2015 Jun; 8(3):367-74. PubMed ID: 25695198
[TBL] [Abstract][Full Text] [Related]
18. Virus safety of human blood, plasma, and derived products.
Guertler L
Thromb Res; 2002 Oct; 107 Suppl 1():S39-45. PubMed ID: 12379292
[TBL] [Abstract][Full Text] [Related]
19. Reduction of virus load in blood donations by screening methods.
Kühnl P; Seidl S; Böhm BO
Curr Stud Hematol Blood Transfus; 1989; (56):9-22. PubMed ID: 2642787
[No Abstract] [Full Text] [Related]
20. Emerging viruses in blood transfusion.
Allain JP
Vox Sang; 1998; 74 Suppl 2():125-9. PubMed ID: 9704434
[No Abstract] [Full Text] [Related]
[Next] [New Search]
